A new type of treatment for osteoarthritis, currently in canine clinical trials, shows promise for eventual use in humans.
The treatment, developed by Cornell biomedical engineers, is a synthetic version of a naturally occurring joint lubricant that binds to the surface of cartilage in joints and acts as a cushion during high-impact activities, such as running.
“When the production of that specific lubricant goes down, it creates higher contact between the surfaces of the joint and, over time, it leads to osteoarthritis,” said David Putnam, a professor in the College of Engineering with appointments in the Meinig School of Biomedical Engineering and the Smith School of Chemical and Biomolecular Engineering.
Putnam is senior author of “Boundary Mode Lubrication of Articular Cartilage With a Biomimetic Diblock Copolymer,” published June 4 in Proceedings of the National Academy of Sciences, USA. Zhexun Sun, a postdoctoral researcher in Putnam’s lab, is the paper’s first author.
The study focuses on a naturally occurring joint lubricant called lubricin, the production of which declines following traumatic injuries to a joint, such as a ligament tear in a knee.
The knee is lubricated in two ways – hydrodynamic mode and boundary mode.
Hydrodynamic mode lubrication occurs when the joint is moving fast and there isn’t a strong force pushing down on it. In this mode, joints are lubricated by compounds like hyaluronic acid (HA) that are thick and gooey, like car oil. There are numerous HA products on the market, approved by the Food and Drug Administration, for treating hydrodynamic mode lubrication disorders.
But HA is ineffective when strong forces are pushing down on the joint, such as those that occur during running or jumping. In these instances, thick gooey HA squirts out from between the cartilage surfaces, and boundary mode lubrication is necessary. Under these forces, lubricin binds to the surface of the cartilage. It contains sugars that hold on to water, to cushion hard forces on the knee.
In the paper, the researchers describe a synthetic polymer they developed that mimics the function of lubricin and is much easier to produce. “We are in clinical trials, with dogs that have osteoarthritis, with our collaborators at Cornell’s College of Veterinary Medicine,” Putnam said.
Those collaborators – Ursula Krotscheck and Kei Hayashi, both associate professors in the Section of Small Animal Surgery in the Department of Clinical Sciences – use a force plate to measure the efficacy of the treatments. The force plate quantifies the amount of force that a dog exerts with each paw, to measure whether they are favoring one paw over another.
“Once we finalize the efficacy study in dogs, we will be in a very good position to market the material for veterinary osteoarthritis treatment,” Putnam said. From there, the human market for a lubricin substitute should follow, just as HA has been made available for human use, mainly in knees.
The Latest on: Osteoarthritis
via Google News
The Latest on: Osteoarthritis
- Discovery that TRPV4 gene regulates cartilage growth might yield future therapies for joint repairon August 24, 2021 at 8:08 am
New information from a study reported in Stem Cells might result in more effective treatments for osteoarthritis and other cartilage diseases, as well as hereditary disorders affecting cartilage ...
- Bad backs costing us big buckson August 24, 2021 at 7:32 am
Bad backs costing us big bucks More money was spent on musculoskeletal disorders, such as osteoarthritis and back pain, than any other disease, condition or injury in Australia, suggests a new report ...
- Bee Venom May Heal Osteoarthritis and Parkinson’s Diseaseon August 24, 2021 at 3:50 am
Angry honeybees produce a richer, better, and more protein-dense bee venom than docile ones, which could further help in the fight against Parkinson's and osteoarthritis.
- PetVivo Changes Brand Name of Signature Osteoarthritis Product to “SPRYNG”on August 23, 2021 at 5:01 am
SPRYNG PetVivo Changes Brand Name of Signature Osteoarthritis Product to “SPRYNG” MINNEAPOLIS, MN, US, Aug. 23, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: PETV) (the "Company") an emerging biomedical device ...
- New Partnership Between OPUM and Thuasne Group Brings AI to Osteoarthritis Bracingon August 22, 2021 at 11:35 pm
Medical device and AI company, OPUM, and orthopedic bracing manufacturer, Thuasne Group, have signed a partnership on a digital solution for non-invasive non-pharmacological treatment of ...
- Sports with bat or racket not tied to thumb-base osteoarthritison August 22, 2021 at 8:30 pm
Repetitive joint use is a risk factor for osteoarthritis, which is a leading cause of disability. Sports requiring a bat or racket to perform repetitive high-velocity impacts may increase ...
- Angry Bees Produce Venom that Could Treat Parkinson, Osteoarthritison August 18, 2021 at 11:26 pm
Researchers at Curtin University revealed that angry bees produce higher quality venom than calm ones. Bee venom is a product widely known for its effective treatment of degenerative and infectious ...
- The Osteoarthritis Action Alliance (OAAA) Receives 5 Years of CDC Funding to Advance National Osteoarthritis (OA) Public Health Initiativeson August 18, 2021 at 12:01 pm
Thanks to additional support from the CDC, the Osteoarthritis Action Alliance is actively addressing the devastating impact of osteoarthritis on adults and communities through strategic leveraging of ...
- Hip Osteoarthritis Pain Drug Market Size – Detailed Analysis of Current Industry Figures with Forecasts Growth By 2025on August 17, 2021 at 6:37 am
The global Hip Osteoarthritis Pain Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 5.3% in the forecast period of 2020 to 2025 and will ...
- Alex Scott, 36, speaks out about osteoarthritis diagnosis amid chronic pain ordealon August 17, 2021 at 4:45 am
ALEX SCOTT was diagnosed with osteoarthritis at just 26-years-old, after suffering an injury on the pitch 10 years ago.
via Bing News